US Fertility Supplement Marketers Don’t Deliver

FDA and FTC jointly warn five marketers of supplements with claims to treat fertility and other reproductive disorders. The unapproved and misbranded drugs could harm consumers and deter them from seeking effective treatments.

One day US regulators are noting an unapproved OTC contraceptive, the next they’re warning companies making unsubstantiated fertility claims for their products.

The Food and Drug Administration and the Federal Trade Commission jointly warned five marketers products labeled as dietary supplements about...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Compliance

Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.

Kratom Industry Argues FDA Wants To Label All Products As Adverse Events Without Evidence

 

Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.

EU Authorities Crack Down On Unauthorized Novel Foods In Supplements

 
• By 

Dietary supplements containing unauthorized novel foods were reported to the European Commission by national regulators on around 40 occasions in the second quarter of 2024.

FSMA Facility, Recall Reinspection Fees Remain On Ice As FDA Heats Up Making Program ‘Feasible’

 

As it has every year since FSMA was passed in 2011, FDA doesn’t plan to impose reinspection fees until it publishes guidance for small businesses to request reductions. FY2025 budget proposal includes plan “to re-structure the fee programs to make it more administratively feasible to operate.”

More from Policy & Regulation

Kratom Industry Argues FDA Wants To Label All Products As Adverse Events Without Evidence

 

Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.

ACNU Switch And IND Exemption Final Rules Targeted For October In FDA Regulatory Goals

 

Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.

'Inside Regulatory Affairs' With The Honest Company’s Sharee Crumbey And Monica Sharda

 
• By 

In this installment of HBW Insight’s “Inside Regulatory Affairs” series, we hear from Sharee Crumbey and Monica Sharda, regulatory affairs specialists at The Honest Company, about the mounting challenges and rewards of the job.